全文获取类型
收费全文 | 4407篇 |
免费 | 278篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 134篇 |
妇产科学 | 100篇 |
基础医学 | 414篇 |
口腔科学 | 67篇 |
临床医学 | 250篇 |
内科学 | 1381篇 |
皮肤病学 | 142篇 |
神经病学 | 283篇 |
特种医学 | 78篇 |
外科学 | 654篇 |
综合类 | 76篇 |
现状与发展 | 2篇 |
一般理论 | 3篇 |
预防医学 | 573篇 |
眼科学 | 93篇 |
药学 | 175篇 |
中国医学 | 22篇 |
肿瘤学 | 239篇 |
出版年
2023年 | 64篇 |
2022年 | 69篇 |
2021年 | 173篇 |
2020年 | 160篇 |
2019年 | 395篇 |
2018年 | 297篇 |
2017年 | 180篇 |
2016年 | 145篇 |
2015年 | 145篇 |
2014年 | 194篇 |
2013年 | 245篇 |
2012年 | 108篇 |
2011年 | 143篇 |
2010年 | 114篇 |
2009年 | 102篇 |
2008年 | 124篇 |
2007年 | 107篇 |
2006年 | 88篇 |
2005年 | 74篇 |
2004年 | 64篇 |
2003年 | 43篇 |
2002年 | 38篇 |
2001年 | 47篇 |
2000年 | 28篇 |
1999年 | 36篇 |
1998年 | 18篇 |
1997年 | 16篇 |
1996年 | 12篇 |
1995年 | 10篇 |
1994年 | 17篇 |
1993年 | 8篇 |
1992年 | 8篇 |
1991年 | 7篇 |
1989年 | 4篇 |
1988年 | 3篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 80篇 |
1984年 | 170篇 |
1983年 | 134篇 |
1982年 | 139篇 |
1981年 | 145篇 |
1980年 | 102篇 |
1979年 | 125篇 |
1978年 | 118篇 |
1977年 | 75篇 |
1976年 | 103篇 |
1975年 | 83篇 |
1974年 | 78篇 |
1973年 | 73篇 |
排序方式: 共有4719条查询结果,搜索用时 15 毫秒
21.
《Vaccine》2020,38(39):6141-6152
Influenza vaccination is considered the most valuable means to prevent and control seasonal influenza infections, which causes various clinical symptoms, ranging from mild cough and fever to even death. Among various influenza vaccine types, the inactivated subunit type is known to provide improved safety with reduced reactogenicity. However, there are some drawbacks associated with inactivated subunit type vaccines, with the main ones being its low immunogenicity and the induction of Th2-biased immune responses. In this study, we investigated the role of a single-stranded RNA (ssRNA) derived from the intergenic region in the internal ribosome entry site of the Cricket paralysis virus as an adjuvant rather than the universal vaccine for a seasonal inactivated subunit influenza vaccine. The ssRNA adjuvant stimulated not only well-balanced cellular (indicated by IgG2a, IFN-γ, IL-2, and TNF-α) and humoral (indicated by IgG1 and IL-4) immune responses but also a mucosal immune response (indicated by IgA), a key protector against respiratory virus infections. It also increases the HI titer, the surrogate marker of influenza vaccine efficacy. Furthermore, ssRNA adjuvant confers cross-protective immune responses against heterologous influenza virus infection while promoting enhanced viral clearance. Moreover, ssRNA adjuvant increases the number of memory CD4+ and CD8+ T cells, which can be expected to induce long-term immune responses. Therefore, this ssRNA-adjuvanted seasonal inactivated subunit influenza vaccine might be the best influenza vaccine generating robust humoral and cellular immune responses and conferring cross-protective and long-term immunity. 相似文献
22.
23.
24.
25.
26.
Byoung Chul Cho Busayamas Chewaskulyong Ki Hyeong Lee Arunee Dechaphunkul Virote Sriuranpong Fumio Imamura Naoyuki Nogami Takayasu Kurata Isamu Okamoto Caicun Zhou Ying Cheng Eun Kyung Cho Pei Jye Voon Jong-Seok Lee Helen Mann Matilde Saggese Thanyanan Reungwetwattana Suresh S. Ramalingam Yuichiro Ohe 《Journal of thoracic oncology》2019,14(1):99-106
Introduction
Here we report efficacy and safety data of an Asian subset of the phase III FLAURA trial (NCT02296125), which compares osimertinib with standard of care (SoC) EGFR tyrosine kinase inhibitors (TKIs) in patients with previously untreated advanced NSCLC with tumors harboring exon 19 deletion (Ex19del)/L858R EGFR TKI–sensitizing mutations.Methods
Eligible Asian patients (enrolled at Asian sites) who were at least 18 years of age (≥20 years in Japan) and had untreated EGFR-mutated advanced NSCLC were randomized 1:1 to receive osimertinib (80 mg, orally once daily) or an SoC EGFR TKI (gefitinib, 250 mg, or erlotinib, 150 mg, orally once daily). The primary end point was investigator-assessed progression-free survival (PFS). The key secondary end points were overall survival, objective response rate, central nervous system efficacy, and safety.Results
The median PFS was 16.5 versus 11.0 months for the osimertinib and SoC EGFR TKI groups, respectively (hazard ratio = 0.54, 95% confidence interval: 0.41–0.72, p < 0.0001). The overall survival data were immature (24% maturity). The objective response rates were 80% for osimertinib and 75% for an SoC EGFR TKI. The median central nervous system PFS was not calculable for the osimertinib group and was 13.8 months for the SoC EGFR TKI group (hazard ratio = 0.55, 95% confidence interval: 0.25–1.17, p = 0.118). Fewer adverse events of grade 3 or higher (40% versus 48%) and fewer adverse events leading to treatment discontinuation (15% versus 21%) were reported with osimertinib versus with an SoC EGFR TKI, respectively.Conclusion
In this Asian population, first-line osimertinib demonstrated a clinically meaningful improvement in PFS over an SoC EGFR TKI, with a safety profile consistent with that for the overall FLAURA study population. 相似文献27.
28.
29.
30.